RecruitingPhase 3NCT07188558

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Studying Diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Lyell Immunopharma, Inc.
Intervention: rondecabtagene autoleucel(biological)
Enrollment: 400 enrolled
Eligibility: 18 years · All sexes
Timeline: 2026 – 2032

Study locations (30)

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Honor Health, Scottsdale, Arizona, United States
Mayo Clinic Arizona, Scottsdale, Arizona, United States
University of Arkansas, Little Rock, Arkansas, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University of California, Los Angeles (UCLA), Los Angeles, California, United States
University of California, Irvine, Orange, California, United States
University of Colorado, Aurora, Colorado, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
AdventHealth, Orlando, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Northside Hospital, Atlanta, Georgia, United States
Northwestern, Chicago, Illinois, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07188558 on ClinicalTrials.gov

Other trials for Diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Diffuse large B-cell lymphoma →

← Back to all trials